Page 4 - Factor Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NUIG researchers developing new cell therapy for severe Covid-19 16 March 2021 print Galway Bay fm newsroom – Researchers at NUI Galway have entered into a international research partnership to develop a new cell therapy for those with severe Covid-19 infection. The partnership, between CÚRAM at NUIG and US-based Factor Bioscience, will also look to treat those with other serious respiratory illnesses. Most people who die of Covid-19 die of acute respiratory distress syndrome, or ARDS. This inflammatory condition causes the lungs to fill with immune cells and fluid, making oxygen transfer ...

Exacis Biotherapeutics Announces Key Addition To Its Executive Leadership Team With Dirk Huebner MD Joining As Chief Medical Officer - Names key executive Dirk Huebner MD, as Chief Medical Officer - Immuno-oncology cell therapy company creates innovative, stealth and performance engineered T and NK cells from induced pluripotent stem cells (iPSCs) - Uses proprietary mRNA-based cell engineering to develop cancer cell therapies - avoids viruses and DNA News provided by Share this article Share this article CAMBRIDGE, Mass., Jan. 29, 2021 /PRNewswire/ -- Exacis Biotherapeutics, Inc., a developm...

Share this article Share this article CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ -- Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced its formation along with completion of in-licensing of certain technologies from Factor Bioscience, a leading cell sciences company. The exclusive license allows Exacis to create allogeneic engineered T and NK cells from induced pluripotent stem cells (iPSC). Exacis' next generation approach avoids use of DNA and viruses by using mRNA. The technologies will be...